CNR1 may reverse progesterone-resistance of endometrial cancer through the ERK pathway
Open Access
- 1 April 2021
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 548, 148-154
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 30 references indexed in Scilit:
- Progesterone Action in Endometrial Cancer, Endometriosis, Uterine Fibroids, and Breast CancerEndocrine Reviews, 2013
- Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin ResistanceCell Metabolism, 2012
- Biomarkers of progestin therapy resistance and endometrial hyperplasia progressionAmerican Journal of Obstetrics and Gynecology, 2012
- Mechanisms of endometrial progesterone resistanceMolecular and Cellular Endocrinology, 2012
- Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometriumFertility and Sterility, 2009
- A high cannabinoid CB1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancerEuropean Journal of Cancer, 2009
- Sparing fertility in young patients with endometrial cancerGynecologic Oncology, 2008
- Multicenter Phase II Study of Fertility-Sparing Treatment With Medroxyprogesterone Acetate for Endometrial Carcinoma and Atypical Hyperplasia in Young WomenJournal of Clinical Oncology, 2007
- Endometrial cancerThe Lancet, 2005
- Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature reviewGynecologic Oncology, 2004